Inhibrx Biosciences (INBX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov25

Inhibrx Biosciences Reports Q3 2025 Earnings and ozekibart Clinical Trial Progress

04:12

Nov15

Inhibrx Biosciences released FY2025 9 Months Earnings on November 14, 2025 (EST), with actual revenue of USD 1.3 M and EPS of USD -6.9325

04:00

Inhibrx Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.28 (forecast USD -1.72)

04:00

Nov14

Inhibrx Biosciences Inc. Reports Q3 2025 Loss and Publishes ozekibart Trial Results

11:00

Nov4

Inhibrx Biosciences Inc. Announces Positive Phase 2 Results for Ozekibart (INBRX-109) in Chondrosarcoma

21:02

Oct30

Inhibrx Reports Positive Phase 2 Results for Ozekibart in Advanced Chondrosarcoma

22:44

Schedules & Filings

Schedules

Filings

Nov14

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -35.26 M, EPS -2.28

Aug13

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.3 M, Net Income -28.65 M, EPS -1.8524

May14

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -43.31 M, EPS -2.8

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change